Table 2

Results of ANCOVAs examining within-group changes in clinical indicators from baseline to months 4 and 10

Month 4 assessmentaMonth 10 assessmentb
nMeans (SD) at month 4Δ From baselinenMeans (SD) at month 10Δ From baseline
HbA1c (%)
 Project Dulce649.0 (1.9)−1.7*569.1 (2.0)−1.5*
 Control subjects819.1 (1.9)−1.1749.7 (2.3)−0.8
Total cholesterol (mg/dL)
 Project Dulce64183.3 (46.1)−11.057186.8 (44.4)−7.2
 Control subjects81187.0 (40.9)−8.574192.1 (51.9)−2.4
HDL (mg/dL)
 Project Dulce6447.3 (12.2)+1.45748.1 (11.7)+1.6
 Control subjects8246.8 (13.5)+0.57447.9 (14.6)+1.7
LDL (mg/dL)
 Project Dulce6099.1 (40.2)−8.15699.4 (36.3)−8.1
 Control subjects80104.3 (34.2)−5.872103.6 (37.7)−7.2
Triglycerides (mg/dL)
 Project Dulce64180.2 (103.7)−28.756182.3 (113.6)−20.0
 Control subjects82192.0 (89.1)−8.473198.6 (128.3)+7.5
Systolic blood pressure (mmHg)
 Project Dulce65119.6 (13.6)−3.257118.9 (14.8)−2.5
 Control subjects82121.7 (17.9)+0.574119.3 (16.6)−1.6
Diastolic blood pressure (mmHg)
 Project Dulce6573.1 (8.1)−1.75771.8 (8.0)−2.2
 Control subjects8274.7 (9.7)−0.77474.8 (8.1)+0.5
BMI
 Project Dulce6430.6 (6.0)−0.15730.9 (6.0)−0.3
 Control subjects8332.3 (6.3)−0.17431.7 (6.4)−0.4
  • aValues reported for participants with baseline and month 4 values (total N: Project Dulce = 66; control subjects = 83; sample sizes for individual analyses are reduced as noted because of missing values).

  • bValues reported for participants with baseline and month 10 values (total N: Project Dulce = 58; control subjects = 75; sample sizes for individual analyses are reduced as noted because of missing values).

  • Change values are calculated using the baseline mean of the subset of participants who completed the follow-up under consideration. All analyses control for age and sex; however, unadjusted means are reported.

  • *P < 0.01.

  • P < 0.05. Two-tailed P values pertain to tests of within-group changes from baseline.